纵向糖化血红蛋白预测孕前糖尿病妊娠不良结局
该回顾性队列研究纳入341例孕前糖尿病妊娠患者,按早期和晚期A1c水平分为控制良好、改善和控制不良三组。结果显示晚期A1c>6.5%与控制不良组多种产科和新生儿不良结局风险增加相关,而控制良好与改善组间多数结局无显著差异,但改善组NICU入住率升高。
要点
- 晚期A1c>6.5%与控制不良组肩难产、早产、NICU入住等风险显著增加相关。
- 控制良好组与改善组多数不良结局无显著差异,但改善组NICU入住率升高。
- 孕期严格血糖控制使晚期A1c<6.5%可降低不良结局,独立于早期血糖控制。
核心结论
- 产前A1c值可用于孕前糖尿病患者的客观风险分层。
- 孕期严格血糖控制使晚期A1c<6.5%可降低产科和新生儿不良结局,独立于早期血糖控制。
研究设计与样本
- 回顾性队列研究,纳入2012年1月至2016年12月Ohio State University Wexner Medical Center所有孕前糖尿病妊娠,且具备早期A1c(<20周)和晚期A1c(>26周)者,共341例。
- 按血糖控制分为良好(早期和晚期A1c<6.5%)、改善(早期A1c>6.5%且晚期A1c<6.5%)和控制不良(晚期A1c>6.5%)三组。
- 采用多因素回归模型计算调整比值比(aOR),控制母亲年龄、BMI、种族/民族、糖尿病类型和分娩孕周,以良好控制组为参照。
主要发现
- 良好组A1c中位数从早期5.7%(IQR 5.4-6.1%)降至晚期5.4%(IQR 5.2-5.7%)。
- 改善组A1c中位数从早期7.5%(IQR 6.7-8.5)降至晚期5.9%(IQR 5.6-6.1)。
- 控制不良组A1c中位数从早期8.3%(IQR 7.1-9.6)降至晚期7.3%(IQR 6.8-7.9)。
- 改善组与良好组相比,除NICU入住率增加(aOR 3.7;CI 1.9-7.3)外,其他不良结局无统计学显著差异。
- 控制不良组与良好组相比,肩难产(aOR 6.8;CI 1.4-34.0)、早产(aOR 3.9;CI 2.1-7.3)、NICU入住(aOR 2.8;CI 1.4-5.3)、呼吸窘迫综合征(aOR 3.0;CI 1.1-8.0)、低血糖(aOR 3.2;CI 1.5-6.9)、大于胎龄儿(aOR 2.7;CI 1.5-4.9)、新生儿住院>4天(aOR 3.1;CI 1.6-6.0)和子痫前期(aOR 2.4;CI 1.2-4.6)风险增加。
关键数值与推荐
- 良好控制:早期和晚期A1c<6.5%。
- 改善:早期A1c>6.5%且晚期A1c<6.5%。
- 控制不良:晚期A1c>6.5%。
- 回归分析未发现剖宫产、脐动脉pH<7.1或5分钟Apgar评分<7的差异。
临床怎么用
- 对孕前糖尿病孕妇应监测早期和晚期A1c以进行风险分层。
- 晚期A1c目标<6.5%有助于降低肩难产、早产、NICU入住等不良结局。
- 即使早期血糖控制不佳,孕期改善至晚期A1c<6.5%仍可获益,但需关注NICU入住风险。
局限性
- 回顾性队列研究设计。
- 样本来自单一医疗中心。
- 未报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although an elevated early pregnancy hemoglobin A1c has been associated with both spontaneous abortion and congenital anomalies, it is unclear whether A1c assessment is of value beyond the first trimester in pregnancies complicated by pregestational diabetes. OBJECTIVE: We sought to investigate the prognostic ability of longitudinal A1c assessment to predict obstetric and neonatal adverse outcomes based on degree of glycemic control in early and late pregnancy. MATERIALS AND METHODS: This was a retrospective cohort study of all pregnancies complicated by pregestational diabetes from January 2012 to December 2016 at The Ohio State University Wexner Medical Center with both an early A1c (<20 weeks' gestation) and late A1c (>26 weeks' gestation) available for analysis. Patients were categorized by good (early and late A1c <6.5%), improved (early A1c >6.5% and late A1c <6.5%) and poor (late A1c >6.5%) glycemic control. A multivariate regression model was used to calculate adjusted odds ratios (aOR) for each identified obstetric and neonatal outcome, controlling for maternal age, body mass index, race/ethnicity, type of diabetes, and gestational age at delivery compared to good control as the referent group. RESULTS: A total of 341 patients met inclusion criteria during the study period. The median A1c values improved from early to late gestation in the good (5.7% [interquartile range [IQR], 5.4-6.1%] versus 5.4%; [IQR 5.2-5.7%]), improved (7.5% [IQR, 6.7-8.5] versus 5.9% [IQR, 5.6-6.1%]) and poor (8.3% [IQR, 7.1-9.6%] versus 7.3% [IQR, 6.8-7.9%]) glycemic control groups. There were no statistically significant differences in the rate of adverse outcomes between the good and improved groups except for an increased rate of neonatal intensive care unit admissions in the improved group (aOR, 3.7; confidence interval [CI], 1.9-7.3). In contrast, the poor control group had an increased rate of shoulder dystocia (aOR, 6.8; CI, 1.4-34.0), preterm delivery (aOR, 3.9; CI, 2.1-7.3), neonatal intensive care unit admission (aOR, 2.8; CI, 1.4-5.3), respiratory distress syndrome (aOR, 3.0; CI, 1.1-8.0), hypoglycemia (aOR, 3.2; CI, 1.5-6.9), large for gestational age weight at birth (aOR, 2.7; CI, 1.5-4.9), neonatal length of stay >4 days (aOR, 3.1; CI, 1.6-6.0) and preeclampsia (aOR, 2.4; CI, 1.2-4.6). There were no differences in rates of cesarean delivery, umbilical artery pH <7.1, or Apgar score <7 at 5 minutes after regression analysis. CONCLUSION: Antenatal hemoglobin A1c values are useful for objective risk stratification of patients with pregestational diabetes. Strict glycemic control throughout pregnancy with a late pregnancy A1c target of <6.5% leads to reduced rates of obstetric and neonatal adverse outcomes independent of early pregnancy glucose control.
引用
- Finneran MM, Kiefer MK, Ware CA, et al. The use of longitudinal hemoglobin A1c values to predict adverse obstetric and neonatal outcomes in pregnancies complicated by pregestational diabetes. Am J Obstet Gynecol MFM. 2019. PMID: 33345983. doi:10.1016/j.ajogmf.2019.100069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。